2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Vaccines, Bispecific Antibody Therapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Bleeding and Clotting, Bleeding Disorders, Platelet Disorders, Thrombocytopenias, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

3009 Diagnostic performance of targeted gene panels and clinical predictors of inherited platelet disorders in children with thrombocytopenia

Andrea Haddad, Cleo Hautefeuille, MD2, Valerie Arsenault3, Alexandra Zabeida4, Tiago Nava5, Nancy Robitaille, MD6, Rochelle Winikoff, MD7, Georges Rivard, MD, FRCPC8, Thai Hoa Tran, MD9, Sonia Cellot, MD, PhD10, Yves Pastore, MD11, Vincent-Philippe Lavallee, MD, PhD12, Thomas Pincez, MD, PhD, FRCPC13, Alexandre Rouette14, Loubna Jouan15, Imene Boumela16
1 University of Montreal, Montreal, Canada
2 CHU Sainte-Justine Azrieli Research Center, Montreal, Quebec, Canada
3 CHU Sainte-Justine Azrieli Research Center, Montreal, Quebec, Canada
4 CHU Sainte-Justine Azrieli Research Center, Montreal, Quebec, Canada
5 CHU Sainte-Justine Azrieli Research Center, Montreal, Quebec, Canada
6 CHU Sainte-Justine Azrieli Research Center, Montreal, Quebec, Canada
7 CHU Sainte-Justine Azrieli Research Center, Montreal, Quebec, Canada
8 CHU Sainte-Justine Azrieli Research Center, Montreal, Quebec, Canada
9 CHU Sainte-Justine Azrieli Research Center, Montreal, Quebec, Canada
10 CHU Sainte-Justine Azrieli Research Center, Montreal, Quebec, Canada
11 CHU Sainte-Justine Azrieli Research Center, Montreal, Quebec, Canada
12 CHU Sainte-Justine Azrieli Research Center, Montreal, Quebec, Canada
13 CHU Sainte-Justine Azrieli Research Center, Montreal, Quebec, Canada
14 CHU Sainte-Justine Azrieli Research Center, Montreal, Quebec, Canada
15 CHU Sainte-Justine Azrieli Research Center, Montreal, Quebec, Canada
16 CHU Sainte-Justine Azrieli Research Center, Montreal, Quebec, Canada

Background

Thrombocytopenia is a common reason for referral to pediatric hematology. While most cases are transient or acquired, a subset of children have an inherited platelet disorder (IPD). IPD are rare monogenic disorders due to variants in ~70 genes. IPD can be associated with abnormal platelet size, aspect and/or function, and extra-hematological features for some. However, IPD may manifest only as mild-to-moderate thrombocytopenia and often remains unrecognized. Diagnosing early IPD is essential to avoid inappropriate treatments, guide clinical management, and provide appropriate genetic counseling. However, it remains unclear which children with unexplained thrombocytopenia are most likely to benefit from genetic panel testing. 

Here, we aimed to determine the diagnostic yield of genetic testing and identify clinical and laboratory predictors of IPD in pediatric patients referred for unexplained thrombocytopenia.

 

Methods

We conducted a retrospective monocentric study in a pediatric tertiary center. We included children (<20 years old) who underwent genetic panel testing for thrombocytopenia between January 2012 and March 2026. During the study period, the number of gene panel expanded from 12 to 69 genes, and genetic testing transitioned from external laboratories to in-house analysis. We used the panel results annotation to define patients with IPD. Definite IPD was defined as the presence of pathogenic or likely pathogenic variants at the heterozygous, hemizygous, or homozygous/compound heterozygous state, depending on the known inheritance of the carrying gene. We considered possible IPD when at least one of the variants carried was a variant of unknown significance (VUS). For the genes with both heterozygous and homozygous possible inheritance, we conservatively considered the gene as having a homozygous/compound heterozygous inheritance. Family history, mean platelet volume (MPV), and blood smear results were extracted from medical records. We used receiver operating characteristic (ROC) curve from logistic regression to compute area under the curve (AUC) and diagnosis performance of factors identified as associated with definite IPD.

 

Results
A total of 70 patients were included. The mean (± standard deviation) age was 9.3 years (± 6.9), with 54 % females and 46 % males. The mean platelet count was 101 × 10?/L (± 56), and the MPV was 11.7 (± 1.6) fL.  A positive family history suggestive of inherited thrombocytopenia in first-degree relatives was present in 17% (12/70) of patients. Panels identified a definite IPD in 6 (9%) patients. The implicated genes were ETV6 (n=2), MYH9 (n=1), RUNX1 (n=1), ACTN1 (n=1), and ANKRD26 (n=1). One patient had an LRBA deficiency. Ten (14%) additional patients had possible IPD with VUS in autosomal dominant genes: MYH9 (n=3), MASTL (n=2), ETV6 (n=1), TUBB1 (n=1), MECOM (n=1), IKZF5 (n=1), and TRPM7 (n=1). Additionally, 4 (6%) patients carried a pathogenic/pathogenic variant in IPD genes, including one in GP1BA, which has a possible heterozygous inheritance.

To identify predictors of a constitutional diagnosis, we compared patients with definite IPD to the others. A positive family history was present in 33 % (2/6) of definite IPD vs 16% (10/54) of others (p=0.59), abnormal platelet size (defined as abnormal MPV and/or abnormal platelet morphology on peripheral blood smear) in 33% (2/6) definite IPD, vs 35/54 (65%) of others (p=0.19), mean platelet count was 57 × 10?/L (± 35) in definite IPD vs. 105 × 10?/L (± 56) in others (p=0.02), and mean age at thrombocytopenia diagnosis was 2 years (± 4) in definite IPD vs. 10 years (±7) in others (p=0.0008). The AUC of a logistic regression model including age at diagnosis and platelet count was 88% with a sensitivity of 83%, a specificity of 88%, a positive predictive value of 42%, and a negative predictive value of 98%.

 

Conclusion

We identified an IPD in ~10% of children investigated for thrombocytopenia involving various genes. Additional patients may also have IPD, but current data does not allow to conclude on the pathogenicity of variants. In this cohort, young age at thrombocytopenia diagnosis and low platelet count were associated with definite IPD. Combining these factors was highly effective at excluding IPD. These data provide information to estimate diagnosis yield and predictive factors of IPD while using targeted gene panels in pediatric unexplained thrombocytopenia.

Andrea Haddad: No relevant conflicts of interest to declare.